| |
Separate univariate models
|
Multivariate modela
|
|---|
|
Clinical variable
|
OR (95 % CI)
|
p value
|
OR (95 % CI)
|
p value
|
|---|
|
Dabigatran vs. VKA
|
0.32 (0.07–1.46)
|
0.141
|
0.40 (0.08–1.88)
|
0.245
|
|
Rivaroxaban vs. VKA
|
0.55 (0.19–1.62)
|
0.28
|
0.65 (0.22–1.98)
|
0.453
|
|
CHADS2: 2 vs. 0–1
|
4.40 (1.54–12.54)
|
0.006
|
4.07 (1.42–11.69)
|
0.009
|
|
CHADS2: ≥3 vs. 0–1
|
3.80 (0.89–16.16)
|
0.071
|
3.19 (0.73–13.99)
|
0.124
|
|
CHA2DS2-VASC: 2 vs. 0–1
|
1.99 (0.38–10.55)
|
0.419
| | |
|
CHA2DS2-VASC: 3 vs. 0–1
|
2.03 (0.36–11.41)
|
0.423
| | |
|
CHA2DS2-VASC: ≥4 vs. 0–1
|
6.30 (1.28–30.95)
|
0.023
| | |
|
HAS–BLED: 2 vs. 0–1
|
2.57 (0.87–7.60)
|
0.089
| | |
|
HAS–BLED: ≥3 vs. 0–1
|
3.11 (0.70–13.80)
|
0.135
| | |
|
Non-banded LAA vs. banded LAA
|
0.64 (0.21–1.99)
|
0.443
| | |
|
Unknown LAA vs. banded LAA
|
0.00 (0.00,∞)
|
0.99
| | |
|
Beta blocker
|
1.64 (0.21–12.84)
|
0.636
| | |
|
Calcium blocker
|
0.21 (0.03–1.61)
|
0.133
| | |
|
Dronedarone
|
1.49 (0.32–6.89)
|
0.61
| | |
|
Statin
|
1.24 (0.49–3.13)
|
0.657
| | |
|
NSAR
|
0.77 (0.17–3.47)
|
0.735
| | |
-
CI confidence interval, LAA left atrial appendage, NSAR non-steroidal anti-rheumatic agents, OR odds ratio, VKA vitamin K antagonists
-
aFinal model resulting from an all-subset variable selection based on Akaike’s Information Criterion; the medication group (dabigatran vs. VKA and rivaroxaban vs. VKA) was defined as fixed covariate, and the significant variables in column 1 were considered as possible covariates
